(Z)-2-amino-5-(2-methylpropylidene)thiazol-4(5H)-one | 1236286-08-0

• 英文名称: (Z)-2-amino-5-(2-methylpropylidene)thiazol-4(5H)-one
• 英文别名: (5Z)-2-imino-5-(2-methylpropylidene)-1,3-thiazolidin-4-one
• CAS: 1236286-08-0
• 化学式: C₇H₁₀N₂OS
• 分子量: 170.235
• InChiKey: YRNYCYKPEAJOBQ-HYXAFXHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  78.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[4-(cyclopropylsulfonyl)phenyl]-3-(tetrahydro-2H-pyran-4-yl)propionic acid 、 (Z)-2-amino-5-(2-methylpropylidene)thiazol-4(5H)-one 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以36%的产率得到(Z)-2-(4-(cyclopropylsulfonyl)phenyl)-N-(5-(2-methylpropylidene)-4-oxo-4,5-dihydro thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide
  参考文献：
  名称：

  Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators

  摘要：

  A series of N-thiazole substituted arylacetamides were designed on the basis of metabolic mechanism of the aminothiazole fragment as glucokinase (GK) activators for the treatment of type 2 diabetes. Instead of introducing a substituent to block the metabolic sensitive C-5 position on the thiazole core directly, a wide variety of C-4 or both C-4 and C-5 substitutions were explored. Compound R-9k bearing an iso-propyl group as the C-4 substituent was found possessing the highest GK activation potency with an EC50 of 0.026 mu M. This compound significantly increased both glucose uptake and glycogen synthesis in rat primary cultured hepatocytes. Moreover, single oral administration of compound R-9k exerted significant reduction of blood glucose levels in both ICR and ob/ob mice. These promising results indicated that compound R-9k is a potent orally active GK activator, and is warranted for further investigation as a new antidiabetic treatment. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.04.038
• 作为产物：
  描述：

  异丁醛 、 假硫代乙内酰脲 在 溶剂黄146 、 β-丙氨酸 作用下， 反应 24.0h， 以35%的产率得到(Z)-2-amino-5-(2-methylpropylidene)thiazol-4(5H)-one
  参考文献：
  名称：

  Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators

  摘要：

  A series of N-thiazole substituted arylacetamides were designed on the basis of metabolic mechanism of the aminothiazole fragment as glucokinase (GK) activators for the treatment of type 2 diabetes. Instead of introducing a substituent to block the metabolic sensitive C-5 position on the thiazole core directly, a wide variety of C-4 or both C-4 and C-5 substitutions were explored. Compound R-9k bearing an iso-propyl group as the C-4 substituent was found possessing the highest GK activation potency with an EC50 of 0.026 mu M. This compound significantly increased both glucose uptake and glycogen synthesis in rat primary cultured hepatocytes. Moreover, single oral administration of compound R-9k exerted significant reduction of blood glucose levels in both ICR and ob/ob mice. These promising results indicated that compound R-9k is a potent orally active GK activator, and is warranted for further investigation as a new antidiabetic treatment. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.04.038

文献信息

• PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS
  申请人：GATTI Richard A.

  公开号：US20130274283A1

  公开（公告）日：2013-10-17

  Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.

  提供了关于早期终止密码子读穿化合物、其组合物以及制备和使用方法的信息。
• Methods to treat lymphoplasmacytic lymphoma
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10597387B2

  公开（公告）日：2020-03-24

  The present invention provides compounds of any one of Formulae (I) to (V) (e.g., compounds of any one of Formulae (I-1) to (I-9)), and methods for treating Waldenström's macroglobulinemia (WM) and other B cell neoplams in a subject using the compounds. The methods comprise administering to a subject in need thereof an effective amount of the compounds. Also provided are methods to treat B cell neoplasms using the compounds in combination with inhibitors of Bruton's tyrosine kinase (BTK), interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), bone marrow on X chromosome kinase (BMX), phosphoinositide 3-kinase (PI3K), transforming growth factor b-activated kinase-1 (TAK1), and/or a Src family kinase.

  本发明提供了式(I)至(V)中任一项的化合物(例如，式(I-1)至(I-9)中任一项的化合物)，以及使用这些化合物治疗受试者的瓦尔登斯特伦巨球蛋白血症(WM)和其他B细胞肿瘤的方法。这些方法包括向有需要的受试者施用有效量的化合物。还提供了使用化合物与布鲁顿酪氨酸激酶（BTK）、白介素-1 受体相关激酶 1（IRAK1）抑制剂联合治疗 B 细胞肿瘤的方法、白细胞介素-1 受体相关激酶 4 (IRAK4)、骨髓 X 染色体激酶 (BMX)、磷酸肌醇 3- 激酶 (PI3K)、转化生长因子 b 激活激酶-1 (TAK1)和/或 Src 家族激酶的抑制剂。
• METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20180186780A1

  公开（公告）日：2018-07-05

  The present invention provides compounds of any one of Formulae (I) to (V) (e.g., compounds of any one of Formulae (I-1) to (I-9)), and methods for treating Waldenström's macroglobulinemia (WM) and other B cell neoplams in a subject using the compounds. The methods comprise administering to a subject in need thereof an effective amount of the compounds. Also provided are methods to treat B cell neoplasms using the compounds in combination with inhibitors of Bruton's tyrosine kinase (BTK), interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), bone marrow on X chromosome kinase (BMX), phosphoinositide 3-kinase (PI3K), transforming growth factor b-activated kinase-1 (TAK1), and/or a Src family kinase.
• US9255088B2
  申请人：——

  公开号：US9255088B2

  公开（公告）日：2016-02-09
• US9908872B2
  申请人：——

  公开号：US9908872B2

  公开（公告）日：2018-03-06